Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Eli Lilly And Co And Boehringer Ingelheim Pharmaceuticals, Inc Initiate Marlina Clinical Trial To Evaluate Use Of Tradjenta (Linagliptin) Tablets In Patients With Type 2 Diabetes And Albuminuria


Tuesday, 19 Mar 2013 08:00am EDT 

Eli Lilly And Co and Boehringer Ingelheim Pharmaceuticals, Inc announced the initiation of a Phase IIIb trial to evaluate the glycemic efficacy and safety of linagliptin in patients with type 2 diabetes with prevalent albuminuria (defined as urinary albumin-to-creatinine ratio (UACR) 30-3000 mg/g creatinine), while remaining on current standard therapy for diabetic nephropathy. The name of the clinical trial is MARLINA (efficacy, safety & Modification of Albuminuria in type 2 diabetes subjects with Renal disease with LINAgliptin), and it can be found on ClinicalTrials.gov under identifier number, NCT01792518. In diabetes, high levels of blood glucose can damage the kidneys' filters. Over time, damage to the kidneys' filters can leave people with type 2 diabetes at risk for developing renal impairment. One of the first signs of damaged kidneys and early-stage renal disease is having the protein albumin leak out of the kidneys into the urine. The primary endpoint of MARLINA is the change from baseline in HbA1c after 24 weeks of treatment. The study is expected to be completed in 2014. 

Company Quote

70.16
0.42 +0.60%
24 Dec 2014